Bill Detail
H.R. 1843
Congress: 119
Title
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Summary
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
Sponsor
Rep. Neal Dunn [R-FL-2]
Status
Referred to the House Committee on Energy and Commerce.
Status as of Nov 13, 2026, 7:16 AM · synced 3d ago
Introduced
2025-03-05
Data source mode: congress-gov
Bill Engagement
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively…
Lobbyists on the case
These are cached disclosure mentions, not verified current representation or confirmed event attendance.
- Chamber of Commerce of the U.S.A.1 filing · 32 lobs
- Caroline Billman2025 Q1
- Neil Bradley2025 Q1
Limited preview · paid intelligence
Keep the intelligence current—not just this one record.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.
Federal Intelligence is $2,500 one-time for three months, or $9,000 for twelve months prepaid, for one named user. Full tracked federal calendar, connected organization/bill/disclosure research, and a private workspace. Fixed terms; no automatic renewal. No demo or scope email is required for standard access.
After verified successful payment, access is activated within one business day and a secure setup link is emailed. Your term starts at activation. These links do not charge you or unlock records. A free alert subscription does not grant full access.